Avant Diagnostics

Avant Diagnostics was a U.S. public precision oncology and diagnostic technology company focused on biomarker assay services and molecular profiling for cancer care. The company initially advanced OvaDx, a pre-symptomatic ovarian cancer screening test, and later shifted emphasis toward the Theralink phosphoprotein biomarker platform after acquiring Amarantus Diagnostics in 2016. Its assays were designed to measure activation states of therapeutic targets and signaling pathways to support treatment selection and companion-diagnostics style applications, especially in oncology. Public disclosures and company-profile sources indicate the business became inactive and is generally described as closed, with the SEC later showing its Exchange Act registration as revoked. Avant appears to have been a diagnostics and healthcare data-generating company rather than a therapeutics developer, so its pipeline was limited to assay offerings rather than a traditional drug pipeline.